A prospective surveillance model for physical rehabilitation of women with breast cancer: Chemotherapy-induced peripheral neuropathy

Cancer

Volumn 118, Issue SUPPL.8, 2012, Pages 2250-2260

  Stubblefield, Michael D ^a,b   McNeely, Margaret L ^c   Alfano, Catherine M ^d   Mayer, Deborah K ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Brachial plexopathy; Breast cancer; Cancer; Chemotherapy; Neuropathy; Pain; Palliative care; Radiculopathy; Rehabilitation; Surveillance; Survivorship

Indexed keywords

AMITRIPTYLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DULOXETINE; FLUOROURACIL; GABAPENTIN; LOCAL ANESTHETIC AGENT; METHOTREXATE; MORPHINE SULFATE; OXYCODONE; PACLITAXEL; PREGABALIN; TRAMADOL; VALPROIC ACID; VENLAFAXINE;

ACUTE DISEASE; ADJUVANT THERAPY; ALTERNATIVE MEDICINE; ASSISTIVE TECHNOLOGY DEVICE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER SURVIVOR; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; ELECTROSTIMULATION THERAPY; EXERCISE; FEMALE; GAIT; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; MORBIDITY; MUSCLE EXCITATION; NEUROPATHIC PAIN; PATIENT ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PHYSICAL PERFORMANCE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLEX; REHABILITATION CARE; REVIEW; SENSATION; STRENGTH; SYMPTOM; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT PLANNING; WALKING AID;

ADULT; AGED; AMERICAN CANCER SOCIETY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONGRESSES AS TOPIC; FEMALE; HUMANS; LONGITUDINAL STUDIES; MASTECTOMY; MIDDLE AGED; NEUROTOXICITY SYNDROMES; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL THERAPY MODALITIES; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84859628561     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27463     Document Type: Review

References (63)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/csr/ 1975-2008/. Based on November 2010 SEER data submission, posted to the SEER Web site, 2011.
2. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(suppl 5):S1-S26.
3. Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E. Chemotherapy-induced neuropathy. Curr Treat Options Neurol. 2011;13:180-190.
4. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol. 2006; 4:398-399. (Pubitemid 44541015)
5. Paice JA. Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs. 2009;25(2 suppl 1):S8-S19.
6. Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN. Small-fiber neuropathy associated with capecitabine (Xeloda)-induced hand-foot syndrome: a case report. J Clin Neuromuscul Dis. 2006;7: 128-132. (Pubitemid 44510079)
7. Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136-222.
8. Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast cancer. Wien Med Wochenschr. 2010;160:174-181.
9. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis. 2010;32:99-122.
10. Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol. 2005;252:1459-1464. (Pubitemid 41803834)
11. Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology. 1995;45:1832-1836.
12. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci. 2006;242:47-54.
13. Martino MA, Miller E, Grendys EC Jr. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol Oncol. 2005;97:710-712. (Pubitemid 40614933)
14. Jerian SM, Sarosy GA, Link CJ Jr, Fingert HJ, Reed E, Kohn EC. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol Oncol. 1993;51:277-280. (Pubitemid 24020378)
15. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304-311. (Pubitemid 24089653)
16. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987;5:1232-1239. (Pubitemid 18045309)
17. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988;61:2192-2195.
18. Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 1991;9:1261-1267.
19. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol. 1992;10:1165-1170.
20. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987;71:1171-1177.
21. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol. 2006;24:1633-1642. (Pubitemid 46638788)
22. Carlson K, Ocean AJ. Peripheral neuropathy with microtubuletargeting agents: occurrence and management approach. Clin Breast Cancer. 2011;11:73-81.
23. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain. 2009;10:1146-1150.
24. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81(4 suppl):S3-S11.
25. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310-318. (Pubitemid 27199100)
26. England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363: 2151-2161. (Pubitemid 38844159)
27. Johnsson KE. Lumbar spinal stenosis. A retrospective study of 163 cases in southern Sweden. Acta Orthop Scand. 1995;66:403-405.
28. Saperstein DS, Barohn RJ. Peripheral neuropathy due to cobalamin deficiency. Curr Treat Options Neurol. 2002;4:197-201.
29. Lopate G, Pestronk A. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol. 2011;13:131-142.
30. England JD, Gronseth GS, Franklin G, et al American Academy of Neurology; American Association of Neuromuscular and Electro-diagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve. 2009;39:116-125.
31. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479-494.
32. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. http://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE-4.03-2010-06-14- QuickReference-8.5x11.pdf.
33. Hile ES, Fitzgerald GK, Studenski SA. Persistent mobility disability after neurotoxic chemotherapy. Phys Ther. 2010;90:1649-1657.
34. Visovsky C, Meyer RR, Roller J, Poppas M. Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs. 2008;12:243-247.
35. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007;11:901-913.
36. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11:361-376.
37. Stubblefield MD. Cancer rehabilitation. Semin Oncol. 2011;38: 386-393.
38. Bril V, England J, Franklin GM, et al American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: Treatment of painful diabetic neuropathy report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3:345-352.
39. Jin D, Xu Y, Geng DF, Yan TB. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2010;89:10-15.
40. Smith TJ, Coyne PJ, Parker GL, Dodson P, Ramakrishnan V. Pilot trial of a patient-specific cutaneous electrostimulation device (MC5- A Calmare®) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage. 2010;40:883-891.
41. Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007;88:1002-1008. (Pubitemid 47126397)
42. Bromberg MB, Smith AG. Handbook of Peripheral Neuropathy. Boca Raton, FL: Taylor & Francis Group; 2005.
43. Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy- induced peripheral neuropathy. Support Care Cancer. 2012;20: 583-589.
44. Chmielewski TL, Hewett TE, Hurd WJ, Snyder-Mackler L. Principles of neuromuscular control for injury prevention and rehabilitation. In: Magee DJ, Zachazewski JE, Quillen WS, ed. Scientific Foundations and Principles of Practice in Musculoskeletal Rehabilitation. Philadelphia, PA: Saunders; 2007:375-387.
45. Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005;9:189-193.
46. Richardson JK, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil. 2001;82:205-209. (Pubitemid 32147889)
47. Richardson JK, Thies SB, DeMott TK, Ashton-Miller JA. Interventions improve gait regularity in patients with peripheral neuropathy while walking on an irregular surface under low light. J Am Geriatr Soc. 2004;52:510-515. (Pubitemid 38480626)
48. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest. 2003;21:439-451. (Pubitemid 37059093)
49. Paice JA. Chronic treatment-related pain in cancer survivors. Pain. 2011;152(3 suppl):S84-S89.
50. Lemoignan J, Chasen M, Bhargava R. A retrospective study of the role of an occupational therapist in the cancer nutrition rehabilitation program. Support Care Cancer. 2010;18:1589-1596.
51. Balducci S, Iacobellis G, Parisi L, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications. 2006;20:216-223. (Pubitemid 43949348)
52. Wonders KY, Reigle BS, Drury DG. Treatment strategies for chemotherapy- induced peripheral neuropathy: potential role of exercise. Oncol Rev. 2010;4:117-125.
53. Pfefer MT. Peripheral neuropathy and neuropathic pain. In: Myers J, Nieman D, eds. ACSM's Resources for Clinical Exercise Physiology: Musculoskeletal, Neuromuscular, Neoplastic, Immunologic and Hematologic Conditions, 2nd ed. Baltimore, MD: Wolters Kluwer Lippincott Williams & Wilkins; 2009:104-112.
54. White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev. 2004;(4): CD003904.
55. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006;175:34-41. (Pubitemid 44065189)
56. Wong R, Sagar S. Acupuncture treatment for chemotherapyinduced peripheral neuropathy-a case series. Acupunct Med. 2006; 24:87-91. (Pubitemid 44048896)
57. Byler JM, Gil KM. Responsibility for long-term care of breast cancer survivors. Breast J. 2011;17:216-217.
58. Sada YH, Street RL Jr, Singh H, Shada RE, Naik AD. Primary care and communication in shared cancer care: a qualitative study. Am J Manag Care. 2011;17:259-265.
59. Smith SL, Singh-Carlson S, Downie L, Payeur N, Wai ES. Survivors of breast cancer: patient perspectives on survivorship care planning. J Cancer Surviv. 2011;5:337-344.
60. Davies NJ, Batehup L. Towards a personalised approach to after-care: a review of cancer follow-up in the UK. J Cancer Surviv. 2011; 5:142-151.
61. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006; 24:5091-5097. (Pubitemid 46631413)
62. Brennan ME, Houssami N. Overview of long term care of breast cancer survivors. Maturitas. 2011;69:106-112.
63. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13:930-936. (Pubitemid 44284897)